Patents Assigned to UAB Research Foundation
-
Patent number: 12486254Abstract: The present disclosure is concerned with substituted uracil compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders associated with the presence of a premature termination codon such as, for example, cystic fibrosis, Duchenne muscular dystrophy, aniridia, Becker muscular dystrophy, spinal muscular atrophy, Hurler syndrome, hemophilia, epidermolysis bullosa (e.g., dystrophic (DEB) form, junctional (JEB) form), Usher syndrome, and cancer, using the compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: February 27, 2023Date of Patent: December 2, 2025Assignees: SOUTHERN RESEARCH INSTITUTE, UAB RESEARCH FOUNDATIONInventors: Kevin Jay Rodzinak, Terry Smalley, Robert Hunter, John P. Tillotson, Corinne E. Augelli-Szafran, Bini Mathew, David Bedwell, Steven Rowe
-
Patent number: 12215108Abstract: The present disclosure is concerned with purine diamine compounds for the treatment of conditions associated with BRD4, RIP3K, and/or IL6 signaling dysfunction such as, for example, cancer (e.g., lung cancer, skin cancer, bladder cancer, kidney cancer, liver cancer), arsenicosis, arsenic poisoning, inflammation, skin lesions, dysfunction of systemic organs, and skin blisters. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: January 10, 2023Date of Patent: February 4, 2025Assignees: Southern Research Institute, UAB Research Foundation, The United States Government as represented by the Department of Veterans AffairsInventors: Mark J. Suto, Bini Mathew, Corinne E. Augelli-Szafran, Marina Fosso Yatchang, Mohammad Athar, Anupam Agarwal, Ritesh Kumar Srivastava, Suhail Muzaffar, Jasim Khan
-
Patent number: 11945781Abstract: The present disclosure is concerned with thioquinolinone compounds for the treatment of disorders associated with heme oxygenase-1 (HO-1) signaling dysfunction such as, for example, kidney diseases (e.g., chronic kidney disease, acute kidney injury). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: March 14, 2023Date of Patent: April 2, 2024Assignees: Southern Research Institute, UAB Research Foundation, The United States Government as represented by the Department of Veterans AffairsInventors: Mark J. Suto, Bini Mathew, Anupam Agarwal, Amie M. Traylor
-
Patent number: 11866416Abstract: The present invention is related to the inhibition of the formation of Streptococci biofilms through the inhibition of glucosyl transferase (Gtf). Compounds, compositions and methods for inhibiting Streptococcus biofilm formation, as well as for preventing, inhibiting and/or treating the formation of dental caries, and methods of identifying compounds that prevent, inhibit and/or treat the formation of dental caries are provided.Type: GrantFiled: April 3, 2019Date of Patent: January 9, 2024Assignee: UAB Research FoundationInventors: Sadanandan E. Velu, Hui Wu, Qiong Zhang, Bhavitavya Nijampatnam
-
Patent number: 11623918Abstract: The present disclosure is concerned with thioquinolinone compounds for the treatment of disorders associated with heme oxygenase-1 (HO-1) signaling dysfunction such as, for example, kidney diseases (e.g., chronic kidney disease, acute kidney injury). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: November 17, 2021Date of Patent: April 11, 2023Assignees: Southern Research Institute, UAB Research Foundation, The United States Government as Represented by the Department of Veterans AffairsInventors: Mark J. Suto, Bini Mathew, Anupam Agarwal, Amie M. Traylor
-
Patent number: 11560413Abstract: The present invention is directed to modified CFTR proteins or fragments thereof that contain single or multiple amino acid mutations to improve the structural stability of such CFTR proteins and/or fragments. Specifically, the modified CFTR proteins or fragment thereof differ from the wild-type human CFTR protein or fragment thereof by the presence of four or more mutations selected from V150D, M470V, S492P, F494N, S495P, A534P, I539T, G550E, G551D, R553Q, R555K, Q637R, S1255L, K1334G, S1359A, E1371Q, H1402S, Q1411D, and any combination thereof, such that the stability of the polypeptide is increased relative to that of the wild-type human CFTR polypeptide or fragment thereof.Type: GrantFiled: February 15, 2019Date of Patent: January 24, 2023Assignees: UAB Research Foundation, Texas Tech University SystemInventors: John C. Kappes, Zhengrong Yang, Christie G. Brouillette, Ina L. Urbatsch
-
Patent number: 11505531Abstract: The present disclosure is concerned with piperazine-2,5-diones that are capable of inhibiting TGF-? and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: August 5, 2019Date of Patent: November 22, 2022Assignees: UAB RESEARCH FOUNDATION, SOUTHERN RESEARCH INSTITUTEInventors: Mark J. Suto, Vandana V. Gupta, Wei Zhang, Joanne Murphy-Ullrich
-
Patent number: 11213507Abstract: Provided is a darwinolide compound having a previously undescribed carbon skeleton and the crystalline form thereof. Also provided are processes of isolating darwinolide, compositions comprising darwinolide, and methods of treating infection, such as a methicillin-resistant Staphylococcus aureus biofilm infection.Type: GrantFiled: April 17, 2017Date of Patent: January 4, 2022Assignees: UNIVERSITY OF SOUTH FLORIDA, UAB RESEARCH FOUNDATIONInventors: Bill J. Baker, Lindsey N. Shaw, James Bruce McClintock, Charles D. Amsler, Jacqueline Lee Fries, Witowski G. Christopher, Renee M. Fleeman
-
Publication number: 20210323933Abstract: The present disclosure is concerned with piperazine-2,5-diones that are capable of inhibiting TGF-? and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: August 5, 2019Publication date: October 21, 2021Applicant: UAB Research FoundationInventors: Mark J. Suto, Vandana V. Gupta, Wei Zhang, Joanne Murphy-Ullrich
-
Publication number: 20210199671Abstract: Provided herein are methods for assessing risk of infection or cardiovascular disease (CVD) in a subject with an inflammatory disease, e.g., rheumatoid arthritis. The methods include performing immunoassays to generate scores based on quantitative data for expression of biomarkers relating to inflammatory biomarkers with or without additional clinical variables to assess infection and CVD risk. Also provided are uses of inflammatory biomarkers for guiding treatment decisions.Type: ApplicationFiled: March 15, 2021Publication date: July 1, 2021Applicants: CRESCENDO BIOSCIENCE, INC., UAB RESEARCH FOUNDATIONInventors: Kerri FORD, Jeffrey R. CURTIS
-
Patent number: 11046729Abstract: The present disclosure is concerned with dipeptide analogs that are capable of inhibiting TGF-? and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, methods for immunotherapy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: October 26, 2018Date of Patent: June 29, 2021Assignees: Southern Research Institute, UAB Research FoundationInventors: Mark J. Suto, Vandana Gupta, Bini Mathew, Joanne Murphy-Ullrich
-
Patent number: 11033535Abstract: The present disclosure is concerned with oxadiazole and thiadiazole analogs that are capable of inhibiting TGF-? and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: March 27, 2020Date of Patent: June 15, 2021Assignees: Southern Research Institute, UAB Research FoundationInventors: Mark J. Suto, Vandana V. Gupta, Bini Mathew, Joanne Murphy-Ullrich
-
Patent number: 10962552Abstract: Provided herein are methods for assessing risk of infection or cardiovascular disease (CVD) in a subject with an inflammatory disease, e.g., rheumatoid arthritis. The methods include performing immunoassays to generate scores based on quantitative data for expression of biomarkers relating to inflammatory biomarkers with or without additional clinical variables to assess infection and CVD risk. Also provided are uses of inflammatory biomarkers for guiding treatment decisions.Type: GrantFiled: March 10, 2020Date of Patent: March 30, 2021Assignees: CRESCENDO BIOSCIENCE, INC., UAB RESEARCH FOUNDATIONInventors: Kerri Ford, Jeffrey R. Curtis
-
Patent number: 10830774Abstract: The present invention provides a method of identifying meningitis as either bacterial meningitis or aseptic meningitis in a subject, comprising: a) measuring the amount of complement C3, complement factor B, complement membrane attack complex (MAC) protein, complement C5b, complement C6, complement C7, complement C8, and/or complement C9 in a cerebrospinal fluid (CSF) sample obtained from the subject; and b) comparing the amount of complement C3, complement factor B, complement MAC protein, complement C5b, complement C6, complement C7, complement C8, and/or complement C9 measured in (a) with the amount of complement C3, complement factor B, complement MAC protein, complement C5b, complement C6, complement C7, complement C8, and/or complement C9 measured in a control sample, wherein an amount of complement C3, complement factor B, complement MAC protein, complement C5b, complement C6, complement C7, complement C8, and/or complement C9 measured in (a) that is greater than the amount of complement C3, complementType: GrantFiled: March 27, 2017Date of Patent: November 10, 2020Assignee: UAB Research FoundationInventors: Scott R. Barnum, Theresa N. Schein, James M. Johnston
-
Publication number: 20200292559Abstract: Provided herein are methods for assessing risk of infection or cardiovascular disease (CVD) in a subject with an inflammatory disease, e.g., rheumatoid arthritis. The methods include performing immunoassays to generate scores based on quantitative data for expression of biomarkers relating to inflammatory biomarkers with or without additional clinical variables to assess infection and CVD risk. Also provided are uses of inflammatory biomarkers for guiding treatment decisions.Type: ApplicationFiled: March 10, 2020Publication date: September 17, 2020Applicants: CRESCENDO BIOSCIENCE, INC., UAB RESEARCH FOUNDATIONInventors: Kerri FORD, Jeffrey R. CURTIS
-
Patent number: 10653747Abstract: Disclosed are synthetic apolipoprotein E-mimicking peptides, derivatives thereof, and related peptides, which are useful as therapeutic agents for reducing plasma cholesterol; synthetic methods of making the peptides; pharmaceutical compositions comprising the peptides, and methods of treating lipid and metabolic disorders using the disclosed synthetic apolipoprotein E-mimicking peptides and compositions thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: July 20, 2015Date of Patent: May 19, 2020Assignees: UAB RESEARCH FOUNDATION, LIPIMETIX DEVELOPMENT, LLCInventors: Gattadahalli M. Anantharamaiah, Dennis Goldberg
-
Patent number: 10653682Abstract: The present disclosure is concerned with oxadiazole and thiadiazole analogs that are capable of inhibiting TGF-? and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: October 26, 2018Date of Patent: May 19, 2020Assignees: Southern Research Institute, UAB Research FoundationInventors: Mark J. Suto, Vandana V. Gupta, Bini Mathew, Joanne Murphy-Ullrich
-
Patent number: 10578702Abstract: An imaging phantom having a housing and a dynamic perfusion assembly positioned within the housing. The dynamic perfusion assembly permits the flow of at least one contrast agent into a non-contrast solution at a desired rate. The dynamic perfusion assembly includes a first chamber that receives at least one contrast agent and a second chamber that receives a non-contrast solution. The second chamber receives the at least one contrast agent from the first chamber at the desired rate.Type: GrantFiled: September 30, 2016Date of Patent: March 3, 2020Assignees: UAB Research Foundation, Southern Research InstituteInventor: Harrison Kim
-
Patent number: 10562844Abstract: Provided herein are compounds of Formula (I), Formula (II), and Formula (III), and compositions comprising the same, as well as methods of use thereof for controlling or inhibiting the formation of calcium oxalate kidney stones, inhibiting the production of glyoxylate and/or oxalate, and/or inhibiting hydroxyproline dehydrogenase (HYPDH).Type: GrantFiled: January 25, 2016Date of Patent: February 18, 2020Assignees: Wake Forest University Health Sciences, UAB Research FoundationInventors: W. Todd Lowther, Ross P. Holmes, Daniel Yohannes
-
Patent number: RE50320Abstract: Disclosed are synthetic apolipoprotein E-mimicking peptides, derivatives thereof, and related peptides, which are useful as therapeutic agents for reducing plasma cholesterol; synthetic methods of making the peptides; pharmaceutical compositions comprising the peptides, and methods of treating lipid and metabolic disorders using the disclosed synthetic apolipoprotein E-mimicking peptides and compositions thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: May 19, 2022Date of Patent: March 4, 2025Assignees: UAB RESEARCH FOUNDATION, ANJI Pharmaceuticals INC.Inventors: Gattadahalli M. Anantharamaiah, Dennis Goldberg